United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine 4.95 g in 5 g

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - brimonidine tartrate, quantity: 5 mg/g (equivalent: brimonidine, qty 3.3 mg/g) - gel - excipient ingredients: carbomer 974p; methyl hydroxybenzoate; phenoxyethanol; glycerol; titanium dioxide; propylene glycol; sodium hydroxide; purified water - mirvaso is indicated for the treatment of facial erythema of rosacea in adult patients

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - brimonidine tartrate - ophthalmic solution - brimonidine tartrate 0.15 %w/v - brimonidine - brimonidine - alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - brimonidine tartrate 0.2%{relative};   - eye drops, solution - 0.2% w/v - active: brimonidine tartrate 0.2%{relative}   excipient: benzalkonium chloride citric acid polyvinyl alcohol sodium chloride sodium citrate sodium hydroxide water for injection - effective for lowering intraocular pressure in patients with ocular hypertension.

Canada - English - Health Canada

alcon canada inc - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

Canada - English - Health Canada

jamp pharma corporation - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

Canada - English - Health Canada

generic medical partners inc - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515), brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brinzolamide 10 mg in 1 ml - simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. simbrinza is contraindicated in patients who are hypersensitive to any component of this product. simbrinza is contraindicated in neonates and infants (under the age of two years) [see use in specific populations (8.4)]. developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (180 times the recommended

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - brimonidine tartrate - ophthalmic solution - brimonidine tartrate 0.15 %w/v - brimonidine - brimonidine - for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Canada - English - Health Canada

pharmascience inc - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists